Bicine

Bicine

SCHEMBL1161531

CC[C@@H](C(=O)O)N(O)O.O=C(O)CN(CCO)CCO

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.42
KDM4E B2RXH2 2/20 0.42
ALOX15 P16050 2/20 0.42
BLM P54132 2/20 0.42
PMP22 Q01453 2/20 0.42
LMNA P02545 1/20 0.42
CHRM2 P08172 1/20 0.42
ADRA2A P08913 1/20 0.42
TSHR P16473 1/20 0.42
DRD1 P21728 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
CYP2C19 P33261 1/20 0.42
ADRA1A P35348 1/20 0.42
DRD3 P35462 1/20 0.42
SLC6A3 Q01959 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
EYA2 O00167 1/20 0.39
APP P05067 1/20 0.39
ACE P12821 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicine SCHEMBL30898941 0.85 KDM4E (0.43) TDP1KDM4EALOX15BLMPMP22
Bicine SCHEMBL22401348 0.79 ALOX15 (0.59) TDP1KDM4EALOX15BLMPMP22
SCHEMBL267577 0.79
SCHEMBL186529 0.79
SCHEMBL11745103 0.77 CHRM1 (0.35) TDP1ADRA1ADRD3SLC6A3
Potassium SCHEMBL30898938 0.77 CA2 (0.39) TDP1TSHRADRA1ADRD3SLC6A3
SCHEMBL31260158 0.77 CHRM1 (0.35) TDP1ADRA1ADRD3SLC6A3MAPT
Bicine SCHEMBL177696 0.77 ALOX15 (0.68) TDP1KDM4EALOX15BLMPMP22
Bicine SCHEMBL34161 0.77 ALOX15 (0.68) TDP1KDM4EALOX15BLMPMP22
SCHEMBL5177311 0.77 TDP1 (0.33) TDP1KDM4EALOX15BLMPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350649-A1 STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING SAME Abbott Laboratories (US) 2011-08-03 EP claimed
EP-1482912-B1 NALTREXONE HYDROCHLORIDE COMPOSITIONS EURO CELTIQUE SA (LU) 2011-05-25 EP claimed
JP-4683842-B2 2011-05-18 JP claimed
US-20240368284-A1 A METHOD OF IMPROVING STABILITY OF IMMUNE CHECK POINT INHIBITORS DR. REDDY'S LABORATORIES LIMITED (IN) 2024-11-07 US disclosed
US-20140249172-A1 INTRANASAL NALTREXONE 3B PHARMACEUTICALS, INC. (US) 2014-09-04 US disclosed
US-20110206680-A1 METHODS FOR TREATING PSORIASIS ABBOTT LABORATORIES (US) 2011-08-25 US disclosed
EP-2350649-A1 STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING SAME Abbott Laboratories (US) 2011-08-03 EP disclosed
US-20110171217-A1 STABLE LIQUID ANTIBODY FORMULATION PFIZER INC 2011-07-14 US disclosed
EP-1482912-B1 NALTREXONE HYDROCHLORIDE COMPOSITIONS EURO CELTIQUE SA (LU) 2011-05-25 EP disclosed
EP-2311491-A1 Composition comprising an antibody against macrophage colony-stimulating factor (M-CSF) and a chelating agent Pharmacia & Upjohn Company LLC (US) 2011-04-20 EP disclosed
EP-2289492-A2 Naltrexone hydrochloride compositions EURO-CELTIQUE S.A. (LU) 2011-03-02 EP disclosed
WO-2011015634-A2 CONTROLLED RELEASE FORMULATIONS OF LIPOCALIN MUTEINS PIERIS AG (DE) 2011-02-10 WO disclosed
US-20110027262-A1 PLATFORM ANTIBODY COMPOSITIONS PHARMACIA & UPJOHN COMPANY LLC 2011-02-03 US disclosed